Century Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

IPSC$1.68-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Year Ended · · Year Ended ·
· · December 31, 2025 · · December 31, 2024 ·
· · · · ·
Cash flows from operating activities · · · ·
Net loss	$(9,580)	$(126,566)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	13,101	13,304
Non-cash operating lease expense (benefit)	1,912	(271)
Stock based compensation	6,840	12,688
Impairment	6,763	4,327
Accretion of investments	(2,357)	(4,812)
Change in fair value of contingent liabilities	(4,534)	(1,356)
Gain on reduction in lease liability due to lease termination	(1,395)	959
Deferred tax (benefit) expense	(73)	870
Change in operating assets and liabilities:
Prepaid expenses and other assets	2,342	543
Operating lease liability	(4,978)	(3,365)
Deferred revenue	(109,164)	(6,589)
Accounts payable	1,562	(1,469)
Accrued expenses and other liabilities	(4,315)	1,602
Net cash used in operating activities	(103,876)	(110,135)

Cash flows from investing activities
Acquisition of property and equipment	(848)	(154)
Acquisition of fixed maturity securities, available for sale	(51,174)	(119,548)
Sale of fixed maturity securities, available for sale	159,523	176,792
Acquisition of Clade Therapeutics, Inc., net of cash acquired	—	(9,608)
Net cash provided by investing activities	107,501	47,482

Cash flows from financing activities

Proceeds from issuance of common stock and ESPP	173	141
Proceeds from ATM, net of issuance costs	—	17,829
Proceeds from PIPE, net of issuance costs	—	56,593
Net cash provided by financing activities	173	74,563

Net increase in cash, cash equivalents, and restricted cash	3,798	11,910

Cash, cash equivalents and restricted cash, beginning of period	61,213	49,303

Cash, cash equivalents and restricted cash, end of period	$65,011	$61,213

Supplemental disclosure of cash and non-cash operating activities:
Reduction of ROU asset and lease liability due to non-cash lease modification	3,892	—
Cash paid for income tax	—	501
	$3,892	$501

Supplemental disclosure of non-cash investing and financing activities:
Issuance of Equity to satisfy contingent liability	$447	$—
Stock issued in connection with the Acquisition	$—	$15,154
Landlord paid leasehold improvements	$—	$934

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.